Yu X, Li F, Klussmann E, Stallone JN, Han G. G proteincoupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. Am J Physiol Endocrinol Metab 307: E398 -E407, 2014. First published July 8, 2014 doi:10.1152/ajpendo.00534.2013.-Activation of GPER exerts a protective effect in hypertension and ischemia-reperfusion models and relaxes arteries in vitro. However, our understanding of the mechanisms of GPER-mediated vascular regulation is far from complete. In the current study, we tested the hypothesis that GPER-induced relaxation of porcine coronary arteries is mediated via cAMP/PKA signaling. Our findings revealed that vascular relaxation to the selective GPER agonist G-1 (0.3-3 M) was associated with increased cAMP production in a concentration-dependent manner. Furthermore, inhibition of adenylyl cyclase (AC) with SQ-22536 (100 M) or of PKA activity with either Rp-8-CPT-cAMPS (5 M) or PKI (5 M) attenuated G-1-induced relaxation of coronary arteries preconstricted with PGF2␣ (1 M). G-1 also increased PKA activity in cultured coronary artery smooth muscle cells (SMCs). To determine downstream signals of the cAMP/PKA cascade, we measured RhoA activity in cultured human and porcine coronary SMCs and myosin-light chain phosphatase (MLCP) activity in these artery rings by immunoblot analysis of phosphorylation of myosin-targeting subunit protein-1 (p-MYPT-1; the MLCP regulatory subunit). G-1 decreased PGF2␣-induced p-MYPT-1, whereas Rp-8-CPT-cAMPS prevented this inhibitory effect of G-1. Similarly, G-1 inhibited PGF2␣-induced phosphorylation of MLC in coronary SMCs, and this inhibitory effect was also reversed by Rp-8-CPT-cAMPS. RhoA activity was downregulated by G-1, whereas G36 (GPER antagonist) restored RhoA activity. Finally, FMP-API-1 (100 M), an inhibitor of the interaction between PKA and A-kinase anchoring proteins (AKAPs), attenuated the effect of G-1 on coronary artery relaxation and p-MYPT-1. These findings demonstrate that localized cAMP/PKA signaling is involved in GPER-mediated coronary vasodilation by activating MLCP via inhibition of RhoA pathway.
to protect against cardiovascular dysfunction (53) . For example, estrogen alone or in combination with a progestin has favorable effects on lipoproteins and fibrinogen (1) , improves vascular inflammation (72) , and restores endothelial function and nitric oxide release, thus promoting vasorelaxation (37) . Estrogen can also act directly on smooth muscle cells to relax arteries (25, 26) and inhibit smooth muscle cell proliferation (67) . Although this evidence strongly suggests that estrogen is indeed vasoprotective, randomized, controlled large trials of hormone replacement therapy such as the Women's Health Initiative showed no cardiovascular benefit for estrogen or estrogen plus progestogen treatment (28, 43) . These apparent conflicting findings warrant further mechanistic study of the effects of estrogen on the vasculature.
The newly reported, membrane-associated G protein-coupled estrogen receptor 1 (GPER; initially called GPR30) is structurally unrelated to nuclear ER␣ or ER␤ (51, 55, 60, 66) . Membrane localization of GPER provides a novel mechanism for rapid, nongenomic responses to estrogen (27, 60) . Evidence that GPER plays an important role in mediating important cardiovascular actions of estrogen is building (24, 40, 47, 49) . GPER activation relaxes rat carotid (9) , rat aorta (41) , human mammary arteries (23) , and coronary arteries (45, 74) with or without endothelium, indicating that GPER acts directly on vascular smooth muscle to regulate vascular tone. The selective GPER agonist G-1 lowers blood pressure in either normotensive (23) or mRen2.Lewis hypertensive rats (41) . Conversely, deletion of Gper increases blood pressure (44) . G-1 improves functional recovery from myocardial ischemia-reperfusion by reducing post-ischemic contractile dysfunction and infarct size, reduces brain infarct size, and prevents strokeinduced immunosuppression in rats (13, 76) . However, because of its novelty, the mechanism by which GPER mediates estrogen action is still unclear (38) .
Estrogen stimulates cAMP production in breast cancer cells via activation of GPER (66) . Various phyto-and xenoestrogens also stimulate cAMP production via GPER either in breast cancer cells or in an ER␣-and ER␤-negative cell line [human embryonic kidney (HEK)-293 cells] that was stably transfected with GPER (65, 66) . Although estrogen-stimulated production of cAMP, a powerful vasodilatory signal, has been demonstrated in rat aortic (15) and porcine coronary artery smooth muscle cells (SMCs) (32) , the role of cAMP in response to GPER activation in coronary arteries is unknown. The key component of generating and sustaining vascular tone is the phosphorylation state of the smooth muscle contractile apparatus myosin light chain (MLC) (34) . It has been reported that cAMP decreases MLC phosphorylation by activating the MLC phosphatase (MLCP) (3, 4) ; however, to the best of our knowledge, a potential link between estrogen, cAMP, and MLC has not been investigated. In this study described here, we tested the hypothesis that GPER activation induces coronary relaxation by activating MLCP via cAMP/PKA signaling.
MATERIALS AND METHODS
Cell culture. Coronary arteries were dissected from porcine hearts obtained from a local abattoir, as described previously (69, 70) , and the protocol was in compliance with the Texas A & M University Institutional Animal Use Protocol. The endothelial layer was gently removed with a cotton-tipped swab, and the media layer was dissected free from the adventitia. The medial layer was then enzymatically dispersed in a 25-cm 2 tissue culture flask and gently shaken (37°C) in 10 ml of dissociation medium, containing (in mM) 110 NaCl, 5 KCl, 2 MgCl2, 0.16 CaCl2, 10 HEPES, 10 NaHCO3, 0.5 KH2PO4, 0.5 NaH2PO4, 0.48 EDTA, 10 taurine, and 10 glucose plus 24 mg of elastase, 6 mg of collagenase, and 15% bovine serum albumin for 3 h. Cells were then dispersed by gentle trituration and centrifuged at 800 rpm for 5 min. The pellet was suspended with coronary artery SMC medium SmGM (Lonza) and seeded in a 25-cm 2 tissue culture flask coated with 1% gelatin. Human coronary artery SMCs were purchased from Life Technologies. Both human and porcine coronary artery SMCs were maintained in SmGM and kept at 37°C under 5% CO 2 in a humidified incubator. The purity of coronary SMCs in culture was verified by positive staining with smooth muscle-specific ␣-actin (39). Passages 2 and 3 of porcine and passage 5 of human coronary artery SMCs were used in this study.
Tension studies. Left anterior descending coronary arteries were dissected from porcine hearts, trimmed of fat and connective tissue, and cut into rings (axial length ϳ5 mm) for isometric contractile force recordings. Rings were endothelium denuded to eliminate effects of endothelium-derived vasoactive factors. Endothelium denudation was confirmed by the absence of dilation to bradykinin (100 nM) exposure. Arterial rings were mounted in isometric myographs (Danish Myograph Technology) filled with 10-ml modified Krebs-Henseleit buffer (in mM): 122 NaCl, 4.7 KCl, 15.5 NaHCO 3, 1.2 KH2PO4, 1.2 MgCl2, 1.8 CaCl2, and 11.5 glucose, pH 7.2, bubbled with 95% O2-5% CO2 (pH 7.4) at 37°C. Two stainless-steel wires were guided through the lumen of the rings. One wire was connected to a force displacement transducer and the other to a stationary micrometer. The preparations were then allowed to equilibrate for 90 min in KrebsHenseleit buffer. During the first 30 min, the arterial rings were gradually stretched until a stable tension of 20 mN was obtained, which was the optimal resting tension determined in preliminary experiments for these preparations. Isometric tension was recorded on a PC computer using the LabChart data acquisition system (AD Instruments). After the initial equilibration, preparations were contracted three times with prostaglandin F2␣ (PGF2␣; 1 M) and then washed and allowed to relax to basal tension. Then preparations were exposed to PGF2␣ (1 M) to induce a stable contraction. When the force reached steady state, G-1 was added in a cumulative manner by increasing the concentration in log increments. Relaxation responses were calculated as the percent reduction in tension at each G-1 concentration from the precontracted state. Pharmacological inhibitors were allowed to equilibrate with the arteries for Ն30 min prior to measurement of a complete G-1 or other vasodilators' concentrationresponse relationships. One ring in each set of experiments was exposed only to the constrictor agent PGF2␣ (1 M) to control for potential fading of the contractile response. In addition, control responses to cumulative amounts of vehicle [dimethylsulfoxide (DMSO)] were measured by adding the identical amount of DMSO used for each concentration of G-1, forskolin, or 6-Bnz-cAMP. The total amount of vehicle never exceeded 0.1%.
Western blot. Standard Western blot analysis was used for detecting phosphorylation of myosin-targeting subunit protein-1 (p-MYPT-1), the regulatory subunit of MLCP, from porcine coronary artery tissue lysates and phosphorylation of MLC from porcine coronary artery SMC lysates. Arterial rings were prepared, mounted in the chamber of the myograph, equilibrated, and contracted three times by PGF2␣ (1 M), as described above. Then preparations were pretreated with inhibitors and G-1 30 min before PGF2␣ (1 M) was added to induce contraction. Artery rings were collected when contraction reached plateau and were snap-frozen in liquid nitrogen. Tissues were pulverized (Fisher Scientific) and then lysed in homogenization buffer of the following composition: 50 mM Tris·HCl, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% SDS, 1% NP-40, and 0.1% deoxycholic acid. For MLC20 phosphorylation detection, porcine coronary artery SMCs were treated with drugs, as indicated in the results. SMCs were harvested and homogenized. Protein concentrations were determined by a detergent-compatible protein assay (BioRad). Proteins were separated by SDS-PAGE with a Mini Protean II (Bio-Rad) gel kit according to the manufacturer's instructions.
Proteins were then transferred to Hybond enhanced chemiluminescence membrane (Amersham Pharmacia Biotech) with a Mini-TransBlot Electrophoretic Transfer Cell (Bio-Rad) at 100 V for 1 h. Membranes were blocked with 5% nonfat milk for 1 h at room temperature and then rinsed with Tris-buffered saline-Tween (TBST) three times for 15 min. Membranes were then probed with primary antibodies in TBST containing 5% nonfat milk protein for overnight at 4°C. The p-MYPT-1 was probed with Thr 853 p-MYPT-1 primary antibody (Santa Cruz Biotechnology), p-MLC was probed with primary antibody p-MLC (Ser 19 ; Cell Signaling Technology), and ␤-actin (Santa Cruz Biotechnology) was used for protein loading control in the densitometry analysis. Experiments were performed in triplicate, and means Ϯ SE were calculated and plotted.
cAMP assay. cAMP production was measured with a cAMP enzyme immunoassay kit according to the manufacturer's instructions (Cayman Chemical), as described previously (78) . Porcine coronary artery SMCs, passages 2-3, were cultured in 35-mm culture dishes in SmGM medium for 2 or 3 days. When cells reached 85-90% confluence, cells were serum-deprived for 18 h in phenol red-free ␣-MEM medium (Invitrogen). Cells were preincubated for 30 min at 37°C in buffer containing 3-isobutyl-1-methylxanthine (100 M) to inhibit phosphodiesterases. Then cells were treated with G-1 (10 nM to 1 M), 0.1% DMSO was used as solvent control, and forskolin (1 M) treatment was used as a positive control.
PKA activity assay. PKA activity was measured by applying the PepTag protein kinase assay (Promega) according to the manufacturer's instructions (8) . Porcine coronary artery SMCs (passage 2) were cultured in 100-mm culture dishes in SmGM medium for 2 days. After being serum-deprived for 18 h, cells were treated with G-1 (100 nM) in the presence or absence of G-36 (1 M) for 30 min; 0.1% DMSO was used as solvent control, forskolin (1 M) was used as a stimulant to mediate PKA activation, and GPER agonist and antagonist were applied as described above. Cells were washed with phosphatebuffered saline and suspended in PKA extraction buffer provided in the assay kit. The crude extracts were assayed on the same day that they were prepared to retain maximal activity. The PKA-specific peptide substrate L-R-R-A-S-L-G (Kemptide) was used for measuring PKA activity. The phosphorylated Kemptide was separated from nonphosphorylated Kemptide by 0.8% agarose electrophoresis. The peptides were imaged under UV light. The image was scanned and quantified by densitometry using ImageJ.
RhoA activity assay and phsophorylation of RhoA detection. RhoA activity was monitored by measuring changes in RhoA-GTP in cultured human and porcine artery SMCs under drug treatments. Briefly, human (passage 5) and porcine (passage 3) coronary artery SMCs were seeded in 60-mm dishes. After 2 days of being grown in the SmGM medium, cells were serum-deprived for 18 h and then treated with drugs as indicated in the results. Cell lysates were collected and protein concentrations from each sample quantified and adjusted for RhoA activity assay and Western blotting. RhoA activity was measured with G-LISA RhoA activation assay biochem kit (Cytoskeleton) according to the manufacturer's instructions by detecting absorbance at 490 nm. RhoA phosphorylated at Ser 188 by PKA was detected by Western blotting using specific antibodies.
Materials. Antibodies were purchased from Santa Cruz Biotechnology. G-1 was purchased from Calbiochem, and 8-(4-chlorophenylthio)adenosine 3=,5=-cyclic monophosphorothioate Rp-isomer (Rp-8-CPT-cAMPS) and N6-benzoyladenosine-3=,5=-cyclic monophosphate (6-Bnz-cAMP) were from Biolog Life Science Institute. PKA inhibitor PKI (14 -22) amide (myristoylated) is from Enzo Life Sciences. 3,3=-Diamino-4,4=-dihydroxydiphenylmethane, 4,4=-methylenebis(2-aminophenol), and bis(3-amino-4-hydroxyphenyl)methane (FMP-API-1) were obtained as described by Christian et al. (11) . All other chemicals were purchased from Sigma-Aldrich.
Statistical analysis. Data are expressed as means Ϯ SE. Significance between two groups was evaluated by Student's t-test for paired data. Comparison between multiple groups was made by two-way ANOVA. P Ͻ 0.05 indicated a significant difference.
RESULTS
cAMP production and coronary relaxation. We and others have reported that GPER activation induces a rapid relaxation of porcine coronary arteries (25, 45, 74) . However, the downstream signaling events in this pathway have yet to be elucidated. GPER activation has been shown to stimulate cAMP production in breast cancer cells (66) . We tested whether activating GPER with G-1 (10 -1,000 nM) stimulated cAMP production in porcine coronary artery SMCs. G-1 at every concentration significantly increased cAMP production compared with the DMSO solvent control group (P Ͻ 0.05; Table 1 ). The stimulation effect was displayed in a concentration-dependent fashion, which closely paralleled the relaxation effect of G-1 (Fig. 1A) . Cumulative addition of G-1 relaxed PGF2␣-precontracted (1 M) endothelium-denuded porcine coronary artery rings (Fig. 1, A and B) and a solvent (DSMO) control were performed, and the weakening of the tension with time was not significant (Table 2) , as we reported previously (74) . The maximal relaxation effect of G-1 was 45.2 Ϯ 8.9%, with an average EC 50 value of 2.67 ϫ 10 Ϫ8 M. These data suggest that cAMP contributes to GPER action in porcine coronary artery reactivity.
The functional role of cAMP. Next, we tested the functional role of cAMP in GPER-mediated coronary artery relaxation. First, the specific adenlylyl cyclase (AC) inhibitor SQ-22536 was used to inhibit cAMP production in these artery rings. As shown in Fig. 2A , SQ-22536 (100 M) markedly decreased G-1-induced relaxation, reaching statistical significance at 300 nM to 30 M, increasing EC 50 of G-1 from 27 to 277 nM (Table 2 ). Then the AC activator forskolin was used to increase cAMP production in these preparations. As expected, forskolin generated a strong concentration-dependent relaxation of endothelium-denuded coronary artery rings. The relaxation response to forskolin reached statistical significance at concentrations as low as 30 nM, and the EC 50 was 101 nM (Table 2 and Fig. 2B ). The maximal effect of 30 M forskolin was a 160.3 Ϯ 21.4% reduction in precontracted tension, also revealing a significant level of resting tone in these rings. These data suggest that cAMP is a powerful vasorelaxant in porcine coronary artery and is involved in the GPER-mediated coronary relaxation.
PKA activity in coronary relaxation. We then tested the effect of PKA, a direct downstream target protein of cAMP, on GPER-mediated relaxation. First, we pretreated the arterial rings with Rp-8-CPT-cAMPS (5 M), a membrane-permeant, phosphodiesterase-resistant, and cAMP-competitive PKA inhibitor. G-1-induced coronary artery relaxation was greatly inhibited by Rp-8-CPT-cAMPS (33.4% inhibition; Fig. 3A and Table 2 ). To further confirm this effect of PKA, we used another PKA inhibitor, the endogenous PKA inhibitor PKI (14 -22) amide (myristoylated). PKI is a small protein that contains a PKA pseudosubstrate sequence. This pseudosubstrate binds to the substrate-binding site of PKA and thus prevents substrate binding and hence, is highly specific for PKA. The myristoyl- Values are given as means Ϯ SE; n ϭ 4. SMCs, smooth muscle cells. Results are standardized by control group. **P Ͻ 0.01 and ***P Ͻ 0.001, significant difference compared with control by using 2-way ANOVA. Fig. 1 . G-1 induces relaxation of precontracted coronary arteries and stimulates cAMP production. A: concentration-response relationship for G-1-induced, endothelium-denuded, prostaglandin F2␣ (PGF2␣)-precontracted (1 M) coronary artery relaxation. Each point represents the mean relaxation effect Ϯ SE. B: cAMP production of the porcine coronary artery smooth muscle cells (SMCs) in response to G-1. Cells were treated for 30 min in serum and phenol red-free DMEM in the presence of 3-isobutyl-1-methylxanthine (100 M) with 0.1% DMSO ϩ G-1 (10 -1,000 nM; for each treatment, n ϭ 4) and forskolin (F; 1 M; n ϭ 4). Each point represents the mean production Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, and ****P Ͻ 0.0001 compared with solvent control (C) group. Results are normalized by total protein amount. ation increases its membrane permeability. Again, the relaxation effect of G-1 was significantly attenuated by inhibiting PKA activity with PKI (14 -22) amide (5 M), the G-1 concentration-response curve shifted to the left with EC 50 at 278 nM ( Fig. 3B and Table 2 ). We then used membranepermeant PKA agonist 6-Bnz-cAMP to mimic the effect of G-1 on coronary relaxation. Like G-1, 6-Bnz-cAMP induced a concentration-dependent relaxation response. However, the relaxation occurred at a much higher concentration (EC 50 ϭ 145.3 M) compared with the parallel G-1 group (EC 50 ϭ 27 nM) (Figs. 1A and 3C), but it caused an almost complete relaxation (96.3%) compared with a maximal G-1-induced relaxation of 44.5% (Table 2) .
To confirm that G-1 indeed stimulates PKA, we measured PKA activity by applying the PepTag protein kinase assay in cultured porcine coronary SMCs at passage 3 (21) , taking the advantage of a high concentration of protein extract from culture cells. As expected, G-1 (100 nM) raised PKA activity twofold compared with the control (Fig. 3D) . To test whether the result is receptor specific, G36, an antagonist of GPER, was applied (12) . G36 (1 M) completely blocked the effect of G-1 (100 nM) and restored PKA activity to the control level (Fig.  3D) , suggesting that the increased PKA activity is indeed induced by GPER activation. Taken together, with results from our tension studies, these findings demonstrate that PKA is involved in GPER-mediated coronary relaxation.
The state of the phosphorylation of MLC/MLCP. Vascular tone depends on the phosphorylation state of the smooth muscle MLC. When MLC is phosphorylated, smooth muscle contracts; when it is dephosphorylated, relaxation ensues. The responsible phosphatase, MLCP, can be activated by dephosphorylation via inhibition of the RhoA/Rho kinase pathway by PKA (4), thus dephosphorylating MLC and causing relaxation.
To gain additional perspective on the mechanisms underlying GPER-induced vasorelaxation, we tested G-1-induced changes in the phosphorylation levels of MLC and MLCP and the contribution of PKA to these alterations. The regulatory subunit of MLCP, MYPT-1, was examined at the Thr Because of the low sensitivity of the available MLC antibodies for porcine coronary tissue, we were not successful in detecting the MLC protein band in these same tissue samples. So we used cultured porcine coronary artery SMCs as an alternative approach to enable us to have greater protein extraction and thus better detection of MLC protein. These experiments would confirm that inhibition of PKA indeed attenuates the effect of G-1 and restores PGF2␣-induced inhibition of MLCP activity. Passage 3 SMCs were treated with PGF2␣ (1 M). As expected, this increased p-MLC. G-1 pretreatment reversed the PGF2␣-induced density of p-MLC levels to control levels. The PKA inhibitor Rp-8-CPT-cAMPS attenuated G-1 effects on p-MLC density (Fig. 4B) .
The status of phosphorylation at Thr 853 of MYPT-1 is in part a manifestation of Rho kinase activity (16) . Therefore, we measured the activity of its upstream protein RhoA in human and porcine coronary SMCs by immunoblotting for the Ser 188 Values are given as means Ϯ SE; no. of experiments is indicated in parentheses. Rp-8-CPT-cAMPS, 3=,5=-cyclic monophosphorothioate Rp-isomer; PKI, PKA inhibitor PKI (14 -22) amide; FMP-API-1, bis(3-amino-4-hydroxyphenyl)methane; 6-Bnz-cAMP, N6-benzoyladenosine-3=,5=-cyclic monophosphate. **P Ͻ 0.01, ***P Ͻ 0.001, and ****P Ͻ 0.0001, significant difference compared with control by using 2-way ANOVA. Artery rings were pretreated with each of the inhibitors in the first 5 rows, and the results were compared with the G-1 alone group (G-1). †DMSO group was used as solvent control; ‡forskolin and 6-Bnz-cAMP were used as vasorelaxant agents, and the results in the last 3 rows were compared with DMSO group. phosphorylation of RhoA (p-RhoA), which leads to inactivation (22) , and measuring directly the activity of RhoA by G-LISA, a way to measure RhoA activation (50) . As expected, the immunoblotting results showed in Fig. 5A that G-1 (1 M) treatment of porcine coronary artery SMCs remarkably induced the phosphorylation of RhoA to an extent similar to that of forskolin (1 M) and 6-Bnz-cAMP (10 M) treatments, and pretreatment with PKI (5 M) completely blocked the response of G-1 treatment, suggesting that activation of GPER inactivates RhoA activity. Consistently, G-LISA RhoA activity measurements in both human and porcine coronary artery SMCs confirmed this response of G-1. Cells were incubated with 10% fetal bovine serum to induce RhoA activity per the manufacturer's (Cytoskeleton) recommendations. Serum increased RhoA activity in both human (ϳ2.5-fold; Fig. 5B ) and porcine coronary artery SMCs (ϳ3-fold; Fig. 5C ). G-1 pretreatment (100 nM, 30 min) significantly inhibited both human and porcine coronary artery SMC RhoA activity by ϳ50% in both types of SMCs. The inhibitory effect of G-1 was restored to control (DMSO) levels by G36 (1 M) pretreatment (Fig. 5 , B and C). Taken together with our vasoreactivity data and Western blot analysis, these findings strongly suggest that GPER activation mediates coronary artery relaxation through activation of MLCP via inhibition of RhoA activity by PKA.
The role of A-kinase anchoring proteins. cAMP/PKA signaling is controlled temporally and spatially by A-kinase anchoring proteins (AKAPs), which confine PKA activity to relevant subsets of its substrates (7, 61) . Figure 3D shows that forskolin raises PKA activity levels higher than G-1, indicating that G-1 activates only a subpool of the total cellular PKA. Therefore, we tested whether AKAPs play a role by interacting with PKA in GPER-mediated coronary artery relaxation. In both isometric tension study and Western blotting, we applied a small molecule, 3,3=-diamino-4,4=-dihydroxydiphenylmethane (FMP-API-1), which inhibits AKAP-PKA interaction and thereby interferes with compartmentalized cAMP/PKA signaling (11) . In the presence of FMP-API-1 (100 M), G-1-induced relaxation of coronary arteries was significantly inhibited. The maximal relaxation was 22.8 Ϯ 9.4%, reaching only about one-half of that in the presence of G-1 alone (44.51 Ϯ 3.21%; Fig. 6A ). In Western blot studies, similarly as described above, p-MYPT-1 was stimulated by PGF2␣ (1 M) and attenuated by G-1 treatment (1 M). FMP-API-1 treatment clearly reversed the effect of G-1 and restored the p-MYPT-1 level to a similar extent as treating the tissues with PGF2␣ alone (Fig. 6B) . Together, these data suggest that interactions between AKAPs and PKA are involved in the cAMP/PKA signaling mediated by GPER in the coronary artery.
DISCUSSION
Convincing evidence has shown that GPER exerts cardiovascular protective effects (24, 49, 57) . However, knowledge of GPER downstream signaling events in the cardiovascular system is lacking. The current study demonstrates for the first time that GPER activation increases cAMP production and activates PKA. With the involvement of AKAPs, PKA inhibits RhoA activity and thereby activates the MLCP, which in turn Bottom: bar graph of the quantitative data of the Western blot bands evaluated by densitometry. Protein amounts were normalized to ␤-actin, which was employed as a control for protein loading. B: RhoA activity in human coronary artery SMCs (passage 5). Cells were treated for 2.5 min with 0.1% DMSO, 10% serum (S), 10% S ϩ G-1 (100 nM), and 10% S ϩ G36 (1 M) ϩ G-1 (100 nM) (n ϭ 3). C: RhoA activity in porcine coronary artery SMCs. Cells were received the same treatment as that of human coronary artery SMCs. *P Ͻ 0.05 (n ϭ 4). dephosphorylates MLC and thus causes coronary artery relaxation.
Although estrogen was first found to enhance cAMP production in human coronary arteries 20 years ago (48), the mechanism whereby estrogen elevates cAMP levels has remained undefined. Recently, studies of nonvascular cells have linked GPER to increased cAMP production. Filardo et al. (18) reported that when GPER-expressing breast cancer cells (i.e., MCF-7 cells with ER␣ and ER␤ present and SKBR3 cells devoid of ER␣ or ER␤ expression) were treated with estrogen, AC was stimulated and caused cAMP-dependent signaling. On the other hand, estrogen treatment of low-level GPER-expressing breast cancer cells (MDA-MB-231 cells expressing ER␤) failed to exhibit cAMP production (18) . However, transfection of GPER into MDA-MB-231 cells greatly increased estrogenstimulated cAMP production in these cells (18) . The increase of cAMP attenuated ERK1/2 activity in those breast cancer cells (18) . Later, Thomas et al. (66) transfected HEK-293 cells with the GPER gene and showed that estrogen treatment of the cells resulted in activation of a stimulatory G protein that was coupled directly to GPER and increased AC activity. Tamoxifen or ICI-182,780 (anti-estrogens now designated as GPER agonists) was found also to increase cAMP production in both of these studies (18, 66) . The effect of the GPER enhancing cAMP production was confirmed in zebrafish oocytes, which are involved in the control of fish oocyte meiotic arrest (54) . In addition, both G-1 and estrogen greatly increased cAMP content along with insulin release in mouse pancreatic islets (5) . While this article was in review, Lindsey et al. (42) reported that both endothelial release of nitric oxide and cAMP were involved in GPER-mediated vasorelaxation in rat mesenteric arteries. However, our previous study demonstrated that activation of GPER-induced porcine coronary artery relaxation is endothelium independent (74) . Apparently, there is heterogeneity in GPER-signaling mechanisms among target vessels and cell types (e.g., nitric oxide dependent vs. nitric oxide independent) (24) . Our current studies revealed that low concentrations of G-1 (e.g., 10 nM) increased cAMP production in coronary smooth muscle cells and caused significant coronary artery relaxation. The stimulatory effect of G-1 on cAMP production paralleled its ability to relax coronary arteries in a concentration-dependent manner. Thus, these experiments are highly indicative of cAMP involvement in the vascular relaxation effect of G-1.
Use of selective cAMP analogs enabled us to test the role of cAMP and its major downstream target PKA in isometric tension studies. Our observation that the AC inhibitor SQ-22536 significantly inhibited G-1-induced coronary relaxation suggested that cAMP mediates GPER-induced relaxation. To verify a role for cAMP in mediating coronary relaxation, we applied 1) the AC activator forskolin to stimulate cellular cAMP production without receptor involvement and 2) the cAMP analog 6-Bnz-cAMP to activate PKA directly. All concentrations of forskolin and higher concentrations of 6-Bnz-cAMP caused a much stronger concentration-dependent relaxation than did G-1. There are several potential explanations for this difference: 1) forskolin is a more potent cAMP activator compared with G-1, as our results showed in Fig. 1, and 2) forskolin has additional effects such as inhibiting the activity of ERK1/2 (63). ERK1/2 has been reported to cause dephosphorylation of caldesmon and inhibition of actin and myosin interaction (14) .
In addition, 6-Bnz-cAMP has an increased metabolic stability against phosphodiesterases compared with cAMP (10). Furthermore, activation of GPER might trigger multiple signaling pathways, some of which could counteract cAMP/PKA signaling. For example, Filardo and colleagues (17, 18) reported that estrogen activation of GPER induced both cAMP production and transactivation of the epidermal growth factor (EGF) receptor through the release of pro-heparan-bound EGF from the cell surface and increased ERK1/2 activity; however, the increase of cAMP production attenuated the ERK1/2 activity a few minutes afterward.
The importance of PKA in GPER-mediated coronary relaxation was further confirmed in our study by applying two highly specific inhibitors: PKI (14 -22) (myristoylated), a membranepermeable PKA inhibitor that binds to the catalytic subunits of PKA (19, 36) ; and Rp-8-CPT-cAMPS, a potent competitive inhibitor of PKA that functions as a cAMP antagonist with high resistance against mammalian phosphodiesterase (10) . Consistently, both of these PKA inhibitors exerted significant inhibition of G-1-induced coronary artery relaxation. These findings strongly suggest that PKA mediates GPER/cAMP downstream signaling. However, we cannot completely dismiss the possibility of the contribution from the alternative cAMP target Epac (exchange protein directly activated by cAMP), which functions as guanine nucleotide exchange factors for the small G protein Rap and plays a role in cardiac contraction and vascular permeability (20) . It is possible that both PKA and Epac are involved in the signaling mediated by GPER in coronary artery relaxation. Currently, the role of the Epac/Rap signaling in GPER-mediated coronary relaxation is under investigation in our laboratory.
Some evidence suggests that ion channels are involved in PKA-mediated vascular smooth muscle relaxation through decreasing intracellular Ca 2ϩ levels. Urocortin-induced, endothelium-independent rat coronary artery relaxation was shown to be mediated primarily through PKA-dependent BK Ca channels opening (29) . Under normoxic conditions, forskolin or a selective PKA agonist opened BK Ca channels in pulmonary artery smooth muscle cells, and these effects could be attenuated by hypoxia (6) . In rat aortic smooth muscle, however, all potassium channels were reported to be responsible for about 80% relaxation induced by the ER␤ activator diarylpropionitrile (ER␤ selective ligand) and mediated by PKA (68) . In rat mesenteric artery, vasoactive intestinal polypeptide caused relaxation through PKA-stimulated K ATP channels (73) . Storeoperated Ca 2ϩ entry was also demonstrated to be involved in coronary artery relaxation mediated by a PKA-dependent mechanism under urocortin treatment (62) . Thus, it seems that ion channels, especially BK Ca channels, play an important role in PKA-mediated vascular smooth muscle relaxation by lowering intracellular Ca . Our previous work demonstrated that BK Ca channels are involved in G-1-induced porcine coronary artery relaxation. Therefore, we speculate that BK Ca channels might be involved in the PKA-dependent mechanism of G-1-induced coronary artery relaxation. However, future study is needed to validate this speculation.
Studies also have demonstrated that cAMP/PKA signaling may inactivate RhoA by phosphorylating RhoA at Ser 188 , thereby releasing the inhibitory effect of RhoA and Rho kinase on MLCP, and therefore allow MLCP to dephosphorylate MLC and relax vascular smooth muscle independent of intra-cellular Ca 2ϩ level (22, 58) . MLCP activity depends largely upon the phosphorylation status of its regulatory subunit MYPT-1 at Thr 696 and Thr 853 . When one or two of these sites is/are dephosphorylated, MLCP will be activated to dephosphorylate MLC and induce relaxation (33) . The increased Rho kinase activity by various vasoconstrictors elevates phosphorylation of MYPT-1 at Thr 853 but not at Thr 696 (16, 35) . Although phosphorylation of MYPT-1 at Thr 696 is insensitive to stimuli by most agonists, it is often spontaneously phosphorylated under resting conditions (33, 35) . Therefore, we only studied the phosphorylation of MYPT-1 at Thr 853 . Our results showed that G-1 treatment induced phosphorylation of RhoA at Ser 188 to a similar extent as that of forskolin and 6-BnzcAMP, attenuated serum-induced RhoA activity in human and porcine coronary smooth muscle cells, and inhibited PGF2␣-induced phosphorylation of MYPT-1 at Thr 853 in porcine coronary artery and that the PKA inhibitor Rp-8-CPT-cAMPS reversed the inhibition effect of G-1. Similarly, in porcine coronary artery SMCs, G-1 treatment decreased phosphorylation of MLC, which was reversed by Rp-8-CPT-cAMPS. These results indicate that cAMP/PKA is involved in the response to G-1, and the result that G-1 increased PKA activity in porcine coronary artery SMCs further confirmed this notion. Consistent with our results, it was reported previously that forskolin and db-cAMP, a PKA activator, inhibited a KClinduced increase in MYPT-1 phosphorylation at Thr 853 and the phosphorylation of MLC, thus relaxing femoral arteries from adult New Zealand white rabbits (56) . Taken together, these findings suggest that through cAMP/PKA signaling, G-1 induced activation of MLCP, which resulted in dephosphorylation of MLC in coronary artery SMCs.
cAMP/PKA signaling is compartmentalized and functions locally by anchoring to the AKAPs (7, 61) . Consistent with this notion, a recent study indicated that the classic estrogen receptors ER␣ and ER␤ are colocalized with AC in the caveolae of vascular SMCs from rat mesenteric arteries and that estrogen increases cAMP production locally, not globally, in these cells (31) . AKAPs are signaling scaffolds that contribute to cAMP signaling in various aspects. They can bind to AC to regulate cAMP synthesis and sequester phosphodiesterases to break down this second messenger locally. In addition, they tether PKA to specific subcellular sites, thereby focusing the activity of PKA toward relevant substrates (7, 52) . In vascular SMCs, studies have shown that the AKAP complex regulates specific vascular SMC functions, such as inhibition of cell migration, by causing localized changes in actin dynamics and reduction in cell proliferation and neointimal hyperplasia by stimulating cAMP-induced transcription and increasing the levels of the cyclin-dependent kinase-2 inhibitor p27kip1 (30, 59) . In addition, the localization of PKA through binding to AKAPs facilitates stimulation of L-type Ca 2ϩ channels in rabbit portal vein SMCs by endogenous PKA (77) . Our novel findings from the current studies reveal that the localization of PKA by binding to AKAPs relaxed coronary smooth muscle through the inhibition of RhoA/Rho kinase (ROCK) signaling. We showed that the small molecule inhibitor of AKAP-PKA interactions, FMP-API-1 (11), significantly inhibited G-1-induced coronary relaxation. Furthermore, FMP-API-1 blocked the inhibitory effect of G-1 on the phosphorylation of MYPT-1 at Thr 853 , which is the target site of ROCK. These results suggest that the binding of PKA to AKAPs is required for GPER-mediated coronary artery relaxation. The relevant isoforms and their localization remain unknown. Their identification is beyond the scope of this study. Candidates involved in controlling relaxation are the three AKAPs reportedly expressed in vascular SMCs: AKAP75 (a membrane AKAP) (26), AKAP5, and gravin (AKAP12) (59) .
In conclusion, we have shown for the first time that GPERmediated porcine coronary relaxation involves localized cAMP/PKA signaling to release the RhoA/ROCK inhibitory effect on MLCP, resulting in decreased phosphorylation of MLC (Fig. 7) . This has implications for GPER regulation of vascular tone in health and disease. Our findings now provide a molecular basis for developing new compounds that better target estrogen signaling for a variety of clinical applications.
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